Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 224

1.

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.

Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, Levis M, Rubin JB, Negrin RR, Estey EH, Konoplev S, Andreeff M, Konopleva M.

Blood. 2009 Jun 11;113(24):6215-24. doi: 10.1182/blood-2008-05-158311. Epub 2008 Oct 27.

2.

Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.

Zeng Z, Samudio IJ, Munsell M, An J, Huang Z, Estey E, Andreeff M, Konopleva M.

Mol Cancer Ther. 2006 Dec;5(12):3113-21.

3.

p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.

Kojima K, McQueen T, Chen Y, Jacamo R, Konopleva M, Shinojima N, Shpall E, Huang X, Andreeff M.

Blood. 2011 Oct 20;118(16):4431-9. doi: 10.1182/blood-2011-02-334136. Epub 2011 Aug 25.

4.

Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.

Sison EA, McIntyre E, Magoon D, Brown P.

Mol Cancer Res. 2013 Sep;11(9):1004-16. doi: 10.1158/1541-7786.MCR-13-0114. Epub 2013 Jun 10.

5.

Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts.

Jacobi A, Thieme S, Lehmann R, Ugarte F, Malech HL, Koch S, Thiede C, Müller K, Bornhäuser M, Ryser M, Brenner S.

Exp Hematol. 2010 Mar;38(3):180-90. doi: 10.1016/j.exphem.2009.12.003. Epub 2009 Dec 24.

6.

Role of CXCR4 in the pathogenesis of acute myeloid leukemia.

Peled A, Tavor S.

Theranostics. 2013;3(1):34-9. doi: 10.7150/thno.5150. Epub 2013 Jan 13. Review.

7.

Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.

Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, Rommel C, Fruman DA, Andreeff M, Konopleva M.

Blood. 2012 Sep 27;120(13):2679-89. Epub 2012 Jul 23.

8.

Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.

Cho BS, Zeng Z, Mu H, Wang Z, Konoplev S, McQueen T, Protopopova M, Cortes J, Marszalek JR, Peng SB, Ma W, Davis RE, Thornton DE, Andreeff M, Konopleva M.

Blood. 2015 Jul 9;126(2):222-32. doi: 10.1182/blood-2015-02-628677. Epub 2015 Jun 1. Erratum in: Blood. 2015 Aug 20;126(8):1049. Konoplev, Sergej [added].

9.

A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment.

Han AR, Lee JY, Kim HJ, Min WS, Park G, Kim SH.

Oncol Rep. 2015 Dec;34(6):2880-8. doi: 10.3892/or.2015.4297. Epub 2015 Sep 21.

PMID:
26398122
10.

Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.

Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, Cortes JE, Ravandi F, Ramachandran A, Andreeff M.

Clin Cancer Res. 2014 May 1;20(9):2363-74. doi: 10.1158/1078-0432.CCR-13-2052. Epub 2014 Mar 11.

11.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M.

J Natl Cancer Inst. 2008 Feb 6;100(3):184-98. doi: 10.1093/jnci/djm328. Epub 2008 Jan 29.

PMID:
18230792
12.
13.

Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.

Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn RA, Hidalgo M.

Neoplasia. 2012 Aug;14(8):690-701.

14.

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.

Weisberg E, Liu Q, Nelson E, Kung AL, Christie AL, Bronson R, Sattler M, Sanda T, Zhao Z, Hur W, Mitsiades C, Smith R, Daley JF, Stone R, Galinsky I, Griffin JD, Gray N.

Leukemia. 2012 Oct;26(10):2233-44. doi: 10.1038/leu.2012.96. Epub 2012 Apr 3.

15.

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.

Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, Prior JL, Piwnica-Worms D, Bridger G, Ley TJ, DiPersio JF.

Blood. 2009 Jun 11;113(24):6206-14. doi: 10.1182/blood-2008-06-162123. Epub 2008 Dec 2.

16.

Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.

Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G.

J Hematol Oncol. 2013 Mar 16;6:21. doi: 10.1186/1756-8722-6-21.

17.

NFATc1 as a therapeutic target in FLT3-ITD-positive AML.

Metzelder SK, Michel C, von Bonin M, Rehberger M, Hessmann E, Inselmann S, Solovey M, Wang Y, Sohlbach K, Brendel C, Stiewe T, Charles J, Ten Haaf A, Ellenrieder V, Neubauer A, Gattenlöhner S, Bornhäuser M, Burchert A.

Leukemia. 2015 Jul;29(7):1470-7. doi: 10.1038/leu.2015.95. Epub 2015 Apr 14.

PMID:
25976987
18.

Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.

Weisberg E, Liu Q, Zhang X, Nelson E, Sattler M, Liu F, Nicolais M, Zhang J, Mitsiades C, Smith RW, Stone R, Galinsky I, Nonami A, Griffin JD, Gray N.

PLoS One. 2013;8(2):e56473. doi: 10.1371/journal.pone.0056473. Epub 2013 Feb 21.

19.

Internal tandem duplication mutations in FLT3 gene augment chemotaxis to Cxcl12 protein by blocking the down-regulation of the Rho-associated kinase via the Cxcl12/Cxcr4 signaling axis.

Onishi C, Mori-Kimachi S, Hirade T, Abe M, Taketani T, Suzumiya J, Sugimoto T, Yamaguchi S, Kapur R, Fukuda S.

J Biol Chem. 2014 Nov 7;289(45):31053-65. doi: 10.1074/jbc.M114.568287. Epub 2014 Sep 18. Erratum in: J Biol Chem. 2015 Nov 20;290(47):28356. Onish, Chie [corrected to Onishi, Chie].

20.

Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis.

Li X, Guo H, Duan H, Yang Y, Meng J, Liu J, Wang C, Xu H.

Sci Rep. 2015 Nov 5;5:16228. doi: 10.1038/srep16228.

Supplemental Content

Support Center